Skip to content

EBIT at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.67M-187%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$5.23M-62.2%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$81.33M-20.3%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Calculated from Perspective Therapeutics’s reported figures.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's EBIT?
Perspective Therapeutics (CATX) reported EBIT of -$28.28M in Q1 2026.
How has Perspective Therapeutics's EBIT changed year-over-year?
Perspective Therapeutics's EBIT decreased by 29.5% year-over-year, from -$21.83M to -$28.28M.
What is the long-term trend for Perspective Therapeutics's EBIT?
Over 3 years (2022 to 2025), Perspective Therapeutics's EBIT has grown at a 145.3% compound annual growth rate (CAGR), from -$7.69M to -$113.56M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.